ArticleBMC cancer2025
Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is shaped by a complex tumor immune microenvironment in which inflammatory mediators like cyclooxygenase-2 (COX-2) and immune checkpoints such as programmed cell death ligand 1 (PD-L1) play central regulatory roles. However, the prognostic significance of these makers, individually and in combination with T-cell infiltration, remains poorly defined.
methodsWe investigated the interplay between PD-L1, COX-2, 15-hydroxy prostaglandin dehydrogenase (15-PGDH), and TILs using both an internal immunohistochemistry (IHC)-based CRC cohort (n = 320) and large public transcriptomic datasets (GSE39582, TCGA-COAD, and E-MTAB-12862). Immune cell composition was analyzed using CIBERSORTx and single-sample gene set enrichment analysis (ssGSEA), and tumors were stratified by consensus molecular subtypes (CMS). Prognostic relevance was evaluated through survival modeling and risk signature development.
resultsPD-L1 expression in the tumor stroma (TS⁺ PD-L1) demonstrated stronger prognostic value than cancer cell-specific PD-L1 (CC+ PD-L1) and correlated positively with COX-2 expression and TIL abundance. Across all cohorts, CD274, PTGS2, and CD8A expression were strongly correlated and enriched in CMS1 tumors. High PTGS2 tumors exhibited inflamed but often immunosuppressive phenotypes, marked by elevated IFN-γ and inflammatory response pathway scores. Multivariate survival analyses confirmed that the combined expression of TS⁺ PD-L1, COX-2, and TIL markers outperformed single-marker models. A composite IHC-based immune-inflammation risk score improved prognostic prediction over TNM staging alone.
conclusionPD-L1 and COX-2 define a conserved immunoregulatory axis in CRC that shapes tumor-immune interactions and impacts prognosis. Integration of TS+ PD-L1, inflammatory markers, and T-cell contexture enhances risk stratification and may inform future immunotherapeutic and chemopreventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.